Please login to the form below

Not currently logged in
Email:
Password:

Antabio bolsters leadership team

The French biopharma appoints four new executives

Antibacterial treatment focused biopharma Antabio has appointed four new executives to strengthen its leadership team.

Gordon Waldron, the firm’s current chairman of the board, heads up Antabio’s finance department on a part time basis.

He joins the biopharma from finance and business development advice firm Sequoia Business Solutions, where he was chief executive officer.

Joining Waldron is Carole Sable, who will oversee Antabio’s clinical strategy.

Sable, has worked for numerous pharmaceutical companies including Vitae Pharmaceuticals, Revolution Medicines and Merck.

She said: “It is exciting to have the opportunity to work on the development of Antabio’s MBLi, which addresses a significant unmet need.”

Leading the firm’s business development dealings is Helmuth van Es, who joins the biopharma from biotech Galapagos, where he was founder.

Furthermore, David Lathbury, who was previously director of process chemistry at AstraZeneca and vice president of chemical development at AMRI, will manage all of Antabio’s CMC activities.

Marc Lemonnier, chief executive officer of Antabio, said: “We are thrilled to have attracted such high calibre talent and these new additions, along with expertise already in house, give Antabio the broad skill sets and high quality international leadership team needed as we embark on the next phase of our growth and move our antibacterial resistance pipeline towards the clinic.”

15th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics